People with recurrent non-infectious uveitis could benefit from a new treatment option
New guidance by NICE has suggested that people with recurrent non-infectious uveitis could benefit from a new treatment option, fluocinolone acetonide implant, Iluvien.
The treatment, which is injected into the eye, lasts three years and could mean fewer hospital visits for patients. Clinical trial results suggested an improvement in visual acuity and a reduction in recurrence rates for uveitis.
NICE director Meindert Boysen, said: ‘Existing treatments for controlling recurrent non-infectious uveitis can be burdensome and disruptive to daily life... The fluocinolone acetonide implant offers patients a new treatment option that could lead to more consistent disease control with a reduced treatment burden.’